Renal Cell Carcinoma Perspective

• S2 Episode 3: Personalized Medicine in Bladder Cancer: Inflection Point   Drs Cheryl Lee and Tom Powles talk about ctDNA and personalized medicine approaches for advanced bladder cancer as we sit at the precipice of change.
  Medscape, May 23, 2023
• S2 Episode 2: How Single-Cell Sequencing Can Help in Renal Cell Carcinoma   Drs Sumanta Pal and David A. Braun discuss the role of single-cell sequencing as a biomarker in renal cell carcinoma, how it is evolving, and how it might apply in other domains.
  Medscape, May 03, 2023
• S2 Episode 1: Tissue Biomarkers and Renal Cell Carcinoma   Drs Sumanta Pal and Scott Haake discuss the biology of kidney cancer and how to incorporate tissue biomarkers into prospective studies on renal cell carcinoma.
  Medscape, May 03, 2023
• AUA 2023 Read clinically focused news coverage of key developments from AUA 2023
  Medscape Urology, April 28, 2023
• Key Abstracts in Renal Cell Carcinoma From ASCO GU 2023   Key data in renal cell carcinoma from ASCO GU 2023 include phase 3 results on girentuximab and updates of CheckMate 9ER and COSMIC-313, which examined combination therapies in the frontline setting.
  Medscape, March 10, 2023
• EAU 2023 Read clinically focused news coverage of key developments from EAU 2023
  Medscape Urology, March 08, 2023
• GUCS 2023 Read clinically focused news coverage of key developments from GUCS 2023
  Medscape Oncology, February 15, 2023
• S1 Episode 6: Second-Line Treatment of Renal Cell Carcinoma   Drs Sumanta Pal and Martin Voss discuss second-line treatment of renal cell carcinoma, including current studies and agents used in the refractory setting.
  Medscape, January 05, 2023
• S1 Episode 5: Biomarkers and Renal Cell Carcinoma   Drs Sumanta Pal and Rana McKay discuss the use of biomarkers in treating patients with renal cell carcinoma to identify whose disease will recur and who will respond to therapy.
  Medscape, December 08, 2022
• Highlights in Metastatic Kidney Cancer Treatment From IKCS 2022   Highlights in kidney cancer from IKCS 2022 include updates on the CLEAR and CheckMate 214 trials, results from the TIVO-3 trial, and early data on a bacterial supplement to enhance immune therapy.
  Medscape, December 01, 2022
• S1 Episode 4: The Microbiome and Renal Cell Carcinoma   Drs Sumanta Pal and Jennifer Wargo discuss how the gut microbiome impacts response to cancer therapy in patients with renal cell carcinoma.
  Medscape, November 02, 2022
• RCC e-Tumor Boards: Case 3: Non-Clear Cell RCC   This case is of a 70-year-old man who initially presents with a right renal mass on a nuclear stress test and is diagnosed with non-clear cell RCC. The team discusses the benefits of genetic testing, hereditary concerns, new treatments, and surgery considerations.
  Medscape, November 01, 2022
• S1 Episode 3: Non-Clear Cell Renal Cell Carcinoma   Drs Sumanta Pal and Mehmet Asim Bilen discuss the complexities of treating patients with non-clear cell renal carcinoma, the nuances of rare subtypes, and when to use chemotherapy vs immunotherapy.
  Medscape, October 04, 2022
• Updates in Renal Cell Carcinoma From ESMO 2022   Positive results with triplet therapy, three adjuvant immunotherapy failures, and promising novel combinations are some of the updates from ESMO Congress 2022 discussed by Dr Eric Jonasch.
  Medscape, September 30, 2022
• S1 Episode 2: Adjuvant Treatment With Immunotherapy   Drs Sumanta Pal and Tian Zhang review the state of the data on adjuvant treatment with immunotherapy for patients with renal cell carcinoma, including where current clinical trials stand.
  Medscape, September 01, 2022
• S1 Episode 1: Frontline Treatment of Renal Cell Carcinoma   Drs Sumanta Pal and Brian Rini discuss frontline treatment of renal cell carcinoma.
  Medscape, September 01, 2022
• S1 Episode 1: Bladder Cancer Choices: Robotic or Open Cystectomy?   Bladder cancer surgeons Drs Cheryl Lee and Khurshid Guru are inspired by a recent Swedish study and discuss aggregate surgical outcomes data comparing their own different approaches.
  Medscape, July 06, 2022
• Highlights in Renal Cell Carcinoma From ASCO 2022   Dr Brian Rini, of Vanderbilt University, reports on key studies in renal cell cancer from ASCO 2022, including results from the EVEREST and CheckMate 9ER trials, and data on a novel AXL inhibitor.
  Medscape, July 05, 2022
• EAU 2022 Read clinically focused news coverage of key developments from EAU 2022
  Medscape Urology, July 01, 2022
• RCC e-Tumor Boards: Case 2: High-Risk Localized RCC   The Kidney Cancer Team from Memorial Sloan Kettering Cancer Center discusses adjuvant treatment strategies for a patient with high-risk localized RCC.
  Medscape, June 01, 2022